Medical Condition News

RSS

Oilfield leader builds unique colored rig to support breast cancer research

If you're seeing pink where you wouldn't normally expect in the Western states, you're not color blind. A Colorado-based company has built the Pink Rig, a hydraulic workover unit with snubbing capabilities that is literally painted pink.

30 Sep 2009

Hearing loss is a concern for all ages: Sonic Innovations

In conjunction with Hearing Aid Awareness Week, Sonic Innovations (www.sonici.com), a Utah-based global hearing aid manufacturer, warns that not being able to hear is more important to your health than you may think. Hearing loss has been linked to depression, anxiety and self-esteem issues.

30 Sep 2009

Study shows that exposure to radon gas leads to lung cancer

Exposure to radon gas in homes is the second leading cause of lung cancer after smoking, according to a study carried out by researchers from the University of Cantabria and the Babes-Bolyai University in Romania. The team has studied data on exposure to this element in a uranium mining area in Transylvania and in an area of granite in Torrelodones, Madrid

30 Sep 2009

Tβ4 therapy in EAE mice improves neurological functional recovery

REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today that researchers at the Henry Ford Health System in Detroit, Michigan, demonstrated for the first time that Tβ4 treatment of EAE (experimental autoimmune encephalomyelitis – an animal model for multiple sclerosis) significantly improves neurological functional recovery.

30 Sep 2009

Sanofi-aventis announces study results comparing efficacy of Lantus to detemir

Sanofi-aventis announced today results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus(R) (insulin glargine (rDNA) injection) compared to twice-daily insulin detemir. The study was presented during the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna.

30 Sep 2009

Researchers identify embryonic origin of Merkel cells

Publication in Journal of Cell Biology : researchers from ULB (IRIBHM) identify the embryonic origin of Merkel cells. Their research continue on an extremely aggressive cancer, the Merkel cell carcinoma

30 Sep 2009

Manic-depression not a lifelong disorder

Bipolar disorder, or manic-depression, causes severe and unusual shifts in mood and energy, affecting a person's ability to perform everyday tasks. With symptoms often starting in early adulthood, bipolar disorder has been thought of traditionally as a lifelong disorder. Now, University of Missouri researchers have found evidence that nearly half of those diagnosed between the ages of 18 and 25 may outgrow the disorder by the time they reach 30.

30 Sep 2009

SATAI invests $1.045 million in Azaya Therapeutics

SATAI (www.satai.us) and the South Texas Regional Center of Innovation and Commercialization (www.strcic.com) today announced an investment of $1.045 million in Azaya Therapeutics, Inc. through the Texas Emerging Technology Fund (ETF) for the commercialization of Azaya’s proprietary Protein Stabilized Nanoparticle (PSN) technology platform to produce targeted, safer and more effective formulations of chemotherapy pharmaceuticals for the treatment of cancer.

30 Sep 2009

Genetic factors play an important role in the development of type 1 diabetes

Under the direction of Prof. Dr. Anette Ziegler, scientists of the Diabetes Research Group at Helmholtz Zentrum München and Technische Universität München investigated the formation of antibodies to a zinc transporter in children with elevated risk for type 1 diabetes. The study provided indications of an early onset of the disease when specific antibodies in the blood and specific variants of the associated zinc transporter are present in the genome.

30 Sep 2009

Plexxikon commences patient dosage in PLX4032 trials for metastatic melanoma

Plexxikon Inc. announces that enrollment has been initiated and the first patient has been treated in the first of two pivotal trials of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation occurring in about 50 percent of melanomas and about eight percent of all solid tumors.

30 Sep 2009

Former professional players have fewer risks of heart attacks

Former professional football players with large bodies don't appear to have the same risk factors for heart disease as their non-athletic counterparts, UT Southwestern Medical Center researchers have found in studying a group of National Football League (NFL) alumni.

30 Sep 2009

Overweight middle-age women could reduce their chances of enjoying a healthy old age: Study

Women who put on weight as they approach middle-age could reduce their chances of enjoying a healthy old age by up to 80%, according to research from the University of Warwick.

30 Sep 2009

New anticoagulant therapy has fewer side-effects than warfarin

In an article reviewed by F1000 Medicine Faculty Members Robert Ruff, Brian Olshansky and Luis Ruilope, the blood-thinner dabigatran is shown to protect against stroke, blood clotting and major bleeding as effectively as warfarin, but with fewer side effects.

30 Sep 2009

Study links physical fitness levels of Spanish teenagers to cardiovascular health

Experts of the Department of Medical Physiology of the University of Granada (EFFECTS-262 research group) are leading a national research to measure the level of physical fitness of Spanish teenagers and its connection with their future cardiovascular health. The study, called AVENA, reveals that the cardiorespiratory fitness level of one out of five teenagers indicates there is a risk of having cardiovascular diseases in the future.

30 Sep 2009

AFRESA Inhalation Powder and AFRESA Inhaler NDA under FDA review

AFRESA® (insulin human [rDNA origin]) Inhalation Powder is a well-tolerated, ultra rapid acting insulin able to more closely replicate normal glucose suppression than currently available insulins, according to data presented at the 45th Annual Meeting of the European Association for the Study of Diabetes.

30 Sep 2009

New treatment for Alzheimer's disease may be in the offing

Oleocanthal, a naturally-occurring compound found in extra-virgin olive oil, alters the structure of neurotoxic proteins believed to contribute to the debilitating effects of Alzheimer's disease. This structural change impedes the proteins' ability to damage brain nerve cells.

30 Sep 2009

Metabolomics identifies biomarkers for periodontitis and gingivitis

...

30 Sep 2009

Metabolic syndrome related to elevated levels of liver enzymes in obese teenagers

Researchers studying a large sample of adolescent American boys have found an association between metabolic syndrome, which is a complication of obesity, and elevated liver enzymes that mark potentially serious liver disease.

30 Sep 2009

Memorial Sloan-Kettering Cancer Center awards $50,000 to three young investigators

Three young investigators who have taken significant steps toward advancing the understanding of cancer will be the recipients of this year's Paul Marks Prize for Cancer Research, a prize awarded biennially since 2001 to scientists under the age of forty-six by Memorial Sloan-Kettering Cancer Center.

30 Sep 2009

Researchers find new ways to treat Myelodysplastic Syndrome

Van Andel Research Institute (VARI) researchers are one step closer to finding new ways to treat Myelodysplastic Syndrome (MDS), a bone marrow disease that strikes up to 15,000 people each year in the United States, and that sometimes results in acute myeloid leukemia.

30 Sep 2009